The short version
- Why people research itLean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
- What the evidence isNo randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
- What to watchSweating, tremor, hunger and confusion, the low glucose pattern.
How IGF-1 DES works
Truncated IGF-1 that barely binds IGFBPs — roughly 10x more potent than native IGF-1, with strong local hyperplastic action.
Des(1-3)IGF-1 is IGF-1 with three amino acids cut off the front. Native IGF-1 is 70 residues; this is 67, missing the N-terminal Gly-Pro-Glu tripeptide.
Why those three residues matter: they are the binding-protein handle. In circulation, almost no IGF-1 is free. It is captured by six IGF binding proteins, and the N-terminal region — with the glutamate at position 3 doing much of the work — is a principal contact for IGFBP binding LeRoith 2021.
- Injectable
Where to get IGF-1 DES
When a vetted partner does, the link and code go here.
Research on IGF-1 DES5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
No completed human trial
Correlative data
DES(1-3)IGF-1 occurs naturally in bovine colostrum and human tissue, and is used widely in cell culture precisely because it is more potent than native IGF-1 in that setting — a laboratory fact rather than a human one.
Reported use is peri-workout and site-specific.
How the mechanism reads
IGF-1 with the first three amino acids removed. That truncation drops its affinity for the IGF binding proteins by roughly an order of magnitude, so it is far more active per unit and far shorter-lived — the opposite design choice from LR3.
MechanisticShort action is the mechanistic argument for peri-workout use and against systemic anabolism, and the same short half-life makes hypoglycemia less likely than with LR3 rather than absent.
Mechanistic
Sources
- LeRoith D, et al. Insulin-like growth factors: Ligands, binding proteins, and receptors. Molecular Metabolism 2021 · PMID 33962049
- Bang P, et al. Frequency and predictive factors of hypoglycemia in patients treated with rhIGF-1: Data from the Eu-IGFD Registry. Journal of Clinical Endocrinology and Metabolism 2023 · PMID 37579214
- Fintini D, et al. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Therapeutics and Clinical Risk Management 2009 · PMID 19707272
- Ramon-Krauel M, et al. Near-adult height outcomes in patients treated with rhIGF-1 for severe growth failure: real-world IGFD Registry data. Journal of Clinical Endocrinology and Metabolism 2025 · PMID 40626687
- Cowan DA, et al. Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration. Drug Testing and Analysis 2022 · PMID 34418311
- Bailes J, Soloviev M. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules 2021 · PMID 33557137
IGF-1 DES safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Diabetes treated with insulin or sulfonylureas, since low blood sugar is its documented risk.
- Active cancer or a precancerous lesion, because it drives local hyperplasia.
- Fasting or very low food intake while using it.
- Diabetic retinopathy.
- Pregnancy, or a teenager with open growth plates and a local growth amplifier.
What’s expected
- Strong local growth signal because it barely binds IGFBPs.
- Hypoglycemia is the documented effect of IGF-1 and this analog maximizes the free fraction.
- Fluid retention and jaw or joint soreness.
Watch for
- Sweating, tremor, hunger and confusion, the low glucose pattern.
- A localized lump or overgrowth.
- Severe headache or vision change.
Labs that tell you it’s working
- Insulin (Fasting): IGF-1 suppresses endogenous insulin, so a low value is expected.
- C-Peptide, Serum: shows whether your own insulin output falls while glucose is low.
- IGF-1: standard assays may misread an analog that does not bind carrier proteins.
- Comprehensive Metabolic Panel: glucose in a fasting draw.
Truncated IGF-1 that barely binds IGFBPs and is roughly ten times more potent locally; hypoglycemia and hyperplasia follow from the free fraction. PMID 37579214 PMID 19707272 PMID 33962049
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
IGF-1 DES FAQ4 common questions
- Is IGF-1 DES approved for human use?
- No. IGF-1 DES is a research compound. No completed randomized human trial has given it yet.
- What is IGF-1 DES researched for?
- Lean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
- Which labs show whether it's doing anything?
- Insulin; C-Peptide, Serum; IGF-1; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for IGF-1 DES: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



